Feature|Articles|April 17, 2024
- Pharmaceutical Executive: April 2024
- Volume 44
- Issue 4
Pharmaceutical Executive: April 2024 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive April 2024 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 2 years ago
Power in Partneringabout 2 years ago
The IRA Impact: Navigating Its Evolving Complexitiesabout 2 years ago
Fighting for Innovationabout 2 years ago
Say Hello to Flexible: Reimagining the Patient Journeyabout 2 years ago
Aspiring for the C-Suite? Consider Being a Chief of Staffabout 2 years ago
Latent Benefit of Access Restrictions for Rare Conditionsabout 2 years ago
The Biotech Rally has Legs—But Rising Tide Isn’t Lifting All Boatsabout 2 years ago
The Pharmaceutical Playbook for Asia’s Private Marketabout 2 years ago
Operating Models for Successful DOL EngagementAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report
2
Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand Strategic Collaboration
3
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
4
Pharma Funding Roundup: Violet Therapeutics' $4.75 Million Seed Extension Financing, Full-Life Technologies Completes $150 Million Financing
5